New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology Annual Meeting

3 years ago

PITTSBURGH, March 26, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal Biotech”) (NASDAQ: KRYS), the leader in redosable gene therapies for…

Evelo Biosciences Presents Late-Breaking Oral Abstract on Data from Phase 2 Trial of EDP1815 in Psoriasis at 2022 American Academy of Dermatology Annual Meeting

3 years ago

CAMBRIDGE, Mass., March 26, 2022 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines…

Amryt Announces Positive Interim Analysis Data From Open Label Phase of EASE Phase 3 Trial in EB

3 years ago

Amryt Announces Positive Interim Analysis Data From Open Label Phase of EASE Phase 3 Trial in EB Late-breaking oral presentation…

Press release: Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis

3 years ago

Late-breaking Phase 3 data at AAD 2022 show Dupixent® (dupilumab) significantly improved signs and symptoms of prurigo nodularis Dupixent significantly…

AnPac Bio-Medical Sciences Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request Hearing

3 years ago

PHILADELPHIA, March 26, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a…

Jasper Therapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

3 years ago

REDWOOD CITY, Calif., March 25, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on…

Oxurion Publishes 2021 Annual Report

3 years ago

Leuven, BELGIUM, Boston, MA, US - March 25, 2022 – 09.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) (the…

Histogen Announces Closing of $4.75 Million Private Placement

3 years ago

SAN DIEGO, March 25, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage company focused on developing potential first-in-class…

US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant

3 years ago

SAN FRANCISCO, March 25, 2022 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced…

Fluidigm Adjourns Special Meeting of Stockholders Until April 1, 2022

3 years ago

Provides Stockholders Additional Time to Consider $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global InvestorsSOUTH SAN FRANCISCO, Calif.,…